CMB International Global Markets | Equity Research | Company Update

## Shennan Circuits (002916 CH)

# Corp Day Takeaways: Company's operation remains normal, little impact from COVID

We hosted an investor call with Shennan during our Technology Corporate Day. There is limited impact from COVID (mainly in logistic) and the Company's operation is normal. We maintain our outlook and previous forecasts for the Company. The utilization rate and production ramp up status are in line with our estimates. Due to limited new capacity added this year, we maintain HOLD rating. TP is RMB102.

- PCB: Limited capacity added in 2022. PCB revenue breakdown by market are 50-60% from Telecom, 13-14% from data center, 10% from industrial/healthcare and 5% from auto. Total utilization rate is ~80%. Domestic telecom business remains weak in 1H22, but is expected to have HoH growth in 2H22, driven by resumed demand for 5G BTS and favorable policy on new infrastructure investments. We expect overseas telecom business to have higher growth but smaller contribution, and remain neutral on telecom PCB segment. For auto PCB, Nantong phase III factory is ramping the production, with ~30% utilization rate. Full capacity is expected to contribute ~RMB1.5bn revenue in late 2023/24E.
- Substrate: demand is strong but new capacity to contribute after 2022. Shenzhen and Wuxi phase I factories are expected to contribute RMB1.0bn-1.2bn and RMB1.3bn with full capacity. Wuxi phase II and Guangzhou factories are planned to begin production by the end of 2022 and 2023. Overall utilization rate for substrate production line is reaching maximum, suggesting continuous high demand. We think the full utilization status will maintain in 2H22. For memory-used substrate (>30% of segment rev.), there is limited new capacity added during the past years across the industry. But the demand for memory is growing, especially driven by data center expansion.
- Maintain HOLD, with unchanged TP of RMB102. There is limited impact from COVID (mainly in logistic) and the company's operation is normal. We maintain our previous rating and TP of RMB102. Potential upside: 1) soonerthan-expected ease of chip shortage, 2) stronger recovery in consumer demand and 3) material cost and logistic overhang removed.

### **Earnings Summary**

- · ·					
(YE 31 Dec)	FY20A	FY21A	FY22E	FY23E	FY24E
Turnover (RMB mn)	11,600	13,943	16,496	19,399	23,080
YoY growth (%)	10.2%	20.2%	18.3%	17.6%	19.0%
Gross margin (%)	26.5%	23.7%	24.9%	25.5%	26.4%
Net profit (RMB mn)	1,430	1,481	1,906	2,337	3,064
EPS (RMB)	3.00	3.02	3.90	4.78	6.26
YoY growth (%)	-18.0%	0.7%	29.0%	22.6%	31.1%
Consensus EPS (RMB)	NA	NA	3.66	4.29	0.00
PE (x)	31.2	31.0	24.0	19.6	14.9
Yield (%)	0.0%	1.0%	1.0%	1.0%	2.2%
ROE (%)	19.2%	17.4%	15.3%	16.5%	18.6%
Net gearing (%)	10.5%	12.9%	Net cash	Net cash	Net cash

Source: Company data, Bloomberg, CMBIGM estimates



### HOLD (Maintain)

Target Price	RM
(Previous TP	RM
Up/Downside	
Current Price	RM

RMB102.00 RMB102.00) +9.1% RMB 93 49

### **China Technology Sector**

Lily Yang, Ph.D. (852) 3916 3716 lilyyang@cmbi.com.hk

Alex Ng (852) 3900 0881 alexng@cmbi.com.hk

Lana Lin (852) 3761 8912 lanalin@cmbi.com.hk



### Stock Data

Mkt Cap (HK\$ mn)	47,949
Avg 3 mths t/o (HK\$ mn)	202
52w High/Low (HK\$)	126.66/85.5
Total Issued Shares (mn)	512.9
Source: Bloomberg	

#### **Shareholding Structure**

AVIC International Holdings	63.97%
HK Securities Clearing	2.69%
China Asset Management Co	0.85%
Source: HKEx	

#### Share Performance

	Absolute	Relative
1-mth	-1.9%	-10.3%
3-mth	-3.2%	-4.2%
6-mth	-15.2%	3.0%
Source: Bloor	nberg	

### 12-mth Price Performance



Source: Bloomberg

### Auditor: BDO



### **Financial Summary**

### Income statement

Income statement						Cash flow					
YE 31 Dec (RMB mn)	FY20A	FY21A	FY22E	FY23E	FY24E	YE 31 Dec (RMB mn)	FY20A	FY21A	FY22E	FY23E	FY24E
Revenue	11,600	13,943	16,496	19,399	23,080	Net profit	1,431	1,481	1,903	2,328	3,055
Cost of sales	(8,530)	(10,637)	(12,386)	(14,451)	(16,989)	D&A	591	793	972	1,057	1,164
Gross profit	3,071	3,306	4,110	4,948	6,090	Change in working capital	(557)	(363)	848	(1,511)	1,138
						Others	335	431	151	114	269
Selling exp	(167)	(233)	(275)	(324)	(385)	Net cash from operating	1,800	2,342	3,874	1,987	5,625
Admin exp (excl. R&D)	(480)	(543)	(643)	(756)	(899)						
R&D exp	(645)	(782)	(926)	(1,089)	(1,295)	Capex	(2,486)	(2,658)	(1,059)	(897)	(1,234)
Finance costs	(152)	(107)	(177)	(180)	(176)	Other	(149)	178	(1,152)	41	47
Other operating exp.	2,889	3,354	4,033	4,736	5,485	Net cash from investing	(2,635)	(2,481)	(2,211)	(855)	(1,187)
Operating profit	1,625	1,617	2,098	2,560	3,361						
						Share issuance	0	0	2,500	0	0
Other non-oper exp.	(19)	(8)	(18)	(16)	(22)	Dividend paid	(453)	(541)	(682)	(835)	(981)
Pre-tax profit	1,606	1,609	2,079	2,544	3,339	Other	383	802	(388)	(611)	(602)
						Net cash from financing	(71)	261	1,430	(1,446)	(1,583)
Income tax expense	(175)	(128)	(177)	(216)	(284)						
Minority interests	1	0	1	1	1	Net change in cash	(905)	122	3,093	(314)	2,855
Net profit	1,430	1,481	1,902	2,327	3,054	Cash at beginning of the year	1,441	504	620	3,713	3,399
						Exchange difference	9	(31)	0	0	0
						Cash at the end of the year	504	620	3,713	3,399	6,254

Balance sheet						Key ratios					
YE 31 Dec (RMB mn)	FY20A	FY21A	FY22E	FY23E	FY24E	YE 31 Dec	FY20A	FY21A	FY22E	FY23E	FY24E
Current assets	5,941	7,270	12,263	13,642	17,801	Revenue mix					
Cash & equivalents	507	620	3,713	3,399	6,254	PCB	8,311	8,737	9,842	11,238	11,033
Account receivables	2,053	2,732	3,046	3,680	4,362	PCBA	1,160	1,940	1,935	1,981	2,080
Inventory	2,206	2,527	2,923	3,471	4,024	Substrate	1,544	2,415	3,783	5,151	8,834
Prepayment	6	16	10	13	15						
Other current assets	1,169	1,377	2,572	3,078	3,145	Growth (%)					
						Revenue	10.2%	20.2%	18.3%	17.6%	19.0%
Non-current assets	8,067	9,522	10,269	10,752	11,523	Gross profit	10.0%	7.6%	24.3%	20.4%	23.1%
PPE	6,485	7,789	8,011	8,180	8,620	Operating profit	14.7%	-0.5%	29.7%	22.1%	31.3%
Deferred tax assets	72	91	103	122	140	Net profit	16.0%	3.5%	28.4%	22.4%	31.2%
Other non-current	1,509	1,642	2,155	2,451	2,762						
Total assets	14,008	16,792	22,532	24,394	29,324	Profit & loss ratio (%)					
						Gross margin	26.5%	23.7%	24.9%	25.5%	26.4%
Current liabilities	4,932	5,948	7,373	7,340	9,758	Operating margin	14.0%	11.6%	12.7%	13.2%	14.6%
ST borrowings	232	350	288	244	173	Net profit margin	12.3%	10.6%	11.5%	12.0%	13.2%
Account payables	1,515	1,881	2,326	2,435	3,248						
Tax payable	22	78	50	83	82	Balance sheet ratio					
Other current liabilities	3,163	3,639	4,710	4,578	6,254	Net debt/total equity (%)	10.5%	12.9%	Net cash	Net cash	Net cash
						Current ratio (x)	1.2	1.2	1.7	1.9	1.8
Non-current liabilities	1,631	2,325	2,723	2,917	3,139	Receivable turnover days	65	63	64	63	64
LT borrowings	1,059	1,368	1,725	1,842	1,995	Inventory turnover days	(79)	(81)	(80)	(81)	(81)
Deferred tax liability	6	7	8	9	10	Payable turnover days	(66)	(58)	(62)	(60)	(61)
Other non-current	566	950	990	1,066	1,134						
Total liabilities	6,563	8,272	10,097	10,257	12,897	Profitability (%)					
						ROE	19.2%	17.4%	15.3%	16.5%	18.6%
Share capital	489	489	489	489	489	ROA	10.2%	8.8%	8.4%	9.5%	10.4%
Reserve	3,660	3,675	6,175	6,175	6,175						
Retained earnings	3,135	4,150	5,565	7,266	9,554	Per share data (RMB)					
Other	158	202	202	202	202	EPS	3.00	3.02	3.89	4.76	6.24
Minority interest	3	3	4	5	6	DPS	0.00	0.95	0.95	0.95	2.05
Total equity	7,444	8,520	12,435	14,137	16,427	BPS	15.61	17.41	25.41	28.89	33.57
Total liabilities and equity	14,008	16,792	22,532	24,394	29,324						

Source: Company data, CMBIGM estimates



### **Disclosures & Disclaimers**

### **Analyst Certification**

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings BUY HOLD SELL NOT RATED	: Stock with potential return of over 15% over next 12 months : Stock with potential return of +15% to -10% over next 12 months : Stock with potential loss of over 10% over next 12 months : Stock is not rated by CMBIGM
OUTPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM	: Industry expected to underperform the relevant broad market benchmark over next 12 months

### CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

### Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM. Additional information on recommended securities is available upon request.

#### For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time)("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

### For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analysts is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

### For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.